Loxapine inhalation powder (Adasuve®)

Assessment Status Rapid Review Complete
Drug Loxapine inhalation powder
Brand Adasuve®
Indication For the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.
Assessment Process
Rapid review commissioned 21/06/2016
Rapid review completed 28/07/2016
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.

Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation.